Dr. John Kellum, Chief Medical Officer of Spectral, noted, “Despite a lower enrollment rate for October we continue to see strong performance across trial sites for screening. Our sites are eager to ...

Detailed price information for Spectral Medical Inc (EDT-T) from The Globe and Mail including charting and trades.

In July 2022, the U.S. FDA granted Breakthrough Device Designation for PMX for the treatment of endotoxic septic shock. Approximately 330,000 patients are diagnosed with septic shock in North America ...

Tigris Trial Enrollment at 135 PatientsStrengthened Balance Sheet with Expected Funds to Complete Tigris Trial Enrollment TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" ...